Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that the Israel Innovation Authority has approved expanded support for its project to advance a robotic aseptic fill & finish platform. Following additional review, the company can now utilize the full approved grant budget of NIS 5 million over two years, with about 66% of that funding being non-dilutive. This grant supports the acquisition and validation of a fully automated robotic-arm aseptic fill & finish system that aligns with EU GMP Annex 1 standards, with validation targeted for the third quarter of 2026.
The investment is part of Scinai’s broader contract development and manufacturing organization (CDMO) expansion strategy, which follows its acquisition of Recipharm Israel Ltd. and a commercial collaboration with Recipharm. This structure strengthens Scinai’s integrated two-site manufacturing platform and enhances sterile biologics capabilities while maintaining disciplined capital allocation through maximized non-dilutive funding. The company’s CDMO unit operates two sites in Israel: a biologics development and clinical manufacturing facility in Jerusalem and a small-molecule API development and GMP manufacturing site in Yavne.
Scinai’s CDMO provides fee-for-service solutions to biotech and pharmaceutical companies, supporting external clients from preclinical development through Phase I/II clinical supply. Services include biologics process development, analytical method development, sterile fill & finish, clinical cGMP manufacturing, and small-molecule API process development and GMP production. Through the strategic collaboration with Recipharm, Scinai offers clients a pathway from early clinical development to late-stage and commercial manufacturing within Recipharm’s global network, enabling continuity and reducing scale-up risk.
In parallel, Scinai is advancing an immunology R&D pipeline, including PC111, a first-in-class anti-FasL monoclonal antibody targeting orphan dermatologic indications, and next-generation NanoAb-based programs in inflammation. The company is seeking strategic partnerships and licensing opportunities to advance these programs toward clinical validation. For more details, the full press release is available at https://ibn.fm/SxadB.
This expanded grant support underscores the importance of non-dilutive funding for biotech companies pursuing capital-intensive manufacturing upgrades. By securing approximately NIS 3.3 million in non-dilutive funds, Scinai can accelerate its robotic fill & finish validation while preserving equity. The move is expected to enhance the company’s competitiveness in the CDMO market and support its long-term growth strategy.
